3 not yet recruiting, 1 recruiting, 1 terminated. 5 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Not yet recruiting 3, Recruiting 1, Terminated 1 |
| Phase 2 | 5 | Not yet recruiting 3, Recruiting 1, Terminated 1 |
Follow B Cell Malignancies: new trials by email Literature Review of B Cell Malignancies trials Research Report on B Cell Malignancies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD19/70 Bi-specific CAR-T Cell Therapy bi-4SCAR CD19/70 T cells - B Cell Malignancies | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-01 | 2026-11-02 |
| CD19/22 Bi-specific CAR-T Cell Therapy bi-4SCAR CD19/22 T cells - B Cell Malignancies | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 60 | 2027-06-01 | 2026-11-02 |
| A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies SHB-02-CD19 (anti CD19 CAR-T cells) - B Cell Malignancies, Acute Lymphobkastic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Sheba Medical Center | 50 | 2026-06-01 | 2026-03-31 |
| CD19/79b Bi-specific CAR-T Cell Therapy bi-4SCAR CD19/79b T cells - B Cell Malignancies | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 60 | 2026-06-01 | 2026-11-02 |
| A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies CD22 CAR-T cells - B Cell Malignancies | Phase 1 / Phase 2 | Recruiting | Sheba Medical Center | 50 | 2026-02-01 | 2026-01-16 |
Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
Shenzhen Geno-Immune Medical Institute (3) · Sheba Medical Center (2)
China (3) · Israel (2)